skip to Main Content
IRBM - First Targeted Protein Degrader Begins Phase I Clinical Trial

First targeted protein degrader begins phase I clinical trial

Despite the fact that less than 20% of the proteome has enzymatic activity, most drug development efforts have so far focused on identifying enzymatic inhibitors. However, targeting a cell’s proteasomal machinery is now considered an effective area of research. As…

DNA IRBM

CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics

19th November 2018, Pomezia, Italy – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).

Back To Top